Lifeboat Foundation

The SARS-CoV-2 pandemic has had an unprecedented impact on global public health and the economy. Although vaccines and antivirals have provided effective protection and treatment, the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells. UNI418 inhibited the proteolytic activation of cathepsins, which is regulated by PIKfyve, resulting in the inhibition of cathepsin L-dependent proteolytic cleavage of the SARS-CoV-2 spike protein into its mature form, a critical step for viral endosomal escape. We also demonstrated that UNI418 prevented ACE2-mediated endocytosis of the virus via PIP5K1C inhibition. Our results identified PIKfyve and PIP5K1C as potential antiviral targets and UNI418 as a putative therapeutic compound against SARS-CoV-2.

Despite the ongoing threat posed by new viruses following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which led to the coronavirus disease 2019 (COVID-19) pandemic, new antiviral drugs continue to be developed to effectively block viral entry into the human body.

Professor Kyungjae Myung and his research team in the Department of Biomedical Engineering, affiliated with the IBS Center for Genomic Integrity, has discovered UNI418, a compound that effectively prevents the penetration of the coronavirus. This compound works by regulating dielectric homeostasis, thereby inhibiting the virus’s entry into human cells.

In the present investigation, the SD rats were separated into two groups old control group and the treatment group (n = 8). The treatment group received four injections of E5 every alternate day for 8 days, and eight injections every alternate day for 16 days. Body weight, grip strength, cytokines, and biochemical markers were measured for more than 400 days of the study. Clinical observation, necropsy, and histology were performed. The E5 treatment exhibited great potential by showing significantly improved grip strength, remarkably decreased pro-inflammatory markers of chronic inflammation and oxidative stress, as well as biomarkers for vital organs (BUN, SGPT, SGOT, and triglycerides), and increased anti-oxidant levels. Clinical examinations, necropsies, and histopathology revealed that the animals treated with the E5 had normal cellular structure and architecture. In conclusion, this unique ‘plasma-derived exosome’ treatment (E5) alone is adequate to improve the health-span and extend the lifespan of the old SD rats significantly.

After an unexpected measurement by the Collider Detector at Fermilab (CDF) experiment in 2022, physicists on the Compact Muon Solenoid experiment (CMS) at the Large Hadron Collider (LHC) announced today a new mass measurement of the W boson, one of nature’s force-carrying particles.

Researchers from the School of Physics & Astronomy have been involved in an important new measurement of the top quark made using data provided by the Large Hadron Collider (LHC).

“The only journey is the one within”

Rainer Maria Rilke

Feedback loops within a system can generate seemingly contradictory or paradoxical relationships. A cognitive system might have an internal model of its mental processes, which influences its decision-making and behavior. This internal model then becomes part of the system’s overall state, creating a recursive loop where the system’s representation of itself affects its own behavior.

Discover how primordial dark energy could unravel astronomy’s greatest puzzles—from the Hubble tension to early galaxy formation—with FreeAstroScience.

Scientists may have unlocked anti-aging secrets by studying a plant cell organelle:

Research team stumble upon new discovery which potentially holds the key to aging in plants. Click here to find out what this means for the future.

I expect this around 2029/2030, so about 5-ish years. Phase 1 of it will be: hey Ai, i didnt really like that level, mission, story line, etc… edits on the fly. Phase 2 of it will be creating DLC on the fly. And, Phase 3 will be just telling an AI roughly what you want to play, and it tries to build it.

Publishing giant Electronic Arts shows a concept of the different ways users could generate their own content in a game using generative AI.